COMPARISON OF THE EFFECT OF A BIOSIMILAR BEVACIZUMAB WITH THE INNOVATORS’ BEVACIZUMAB IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER
Journal Title: European Journal of Biomedical and Pharmaceutical Sciences - Year 2019, Vol 6, Issue 2
Abstract
Aim: The role of bevacizumab in combination with carboplatin/paclitaxel chemotherapy has been established in patients with non-small-cell lung cancer (NSCLC). This trial was designed to compare the effect of the Zydus biosimilar bevacizumab with the reference bevacizumab in patients with NSCLC. Methods: A multicentre, prospective, randomized, open-label, active controlled study was carried out on 248 subjects with advanced, unresectable, recurrent or metastatic NSCLC at 28 sites across India. Subjects were randomized in a 2:1 ratio to receive intravenous infusion of 15 mg/kg of test or reference bevacizumab, plus paclitaxel 175 mg/m2 and carboplatin (AUC 5 mg/mL×min) every 3 weeks for 6 cycles. Overall response rate (ORR) after 6 cycles was assessed by using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Pharmacokinetics, safety and tolerability, and immunogenicity were also assessed. Results: The ORR was 60.82% responders in the Zydus bevacizumab and 58.82% responders in the reference bevacizumab and the 90% confidence interval (CI) for the difference of ORR fell within the ±20% equivalence margin (-11.96, 15.97). The pharmacokinetic assessment of the Ln-transformed bevacizumab after Cycle-1 data showed the 90% CI for the ratio of the test to reference geometric least square mean fell within the 80.00-125.00% limits for Cmax (87.99%; 120.41%) and AUC0-t (90.70%; 122.03%). The incidence of immunogenicity was marginally lower in the test group as compared to the reference group (72.16% vs. 76.47%). Conclusion: The results demonstrated biosimilarity between Zydus and reference bevacizumab with respect to efficacy, tolerability and safety in the patients with NSCLC.
Authors and Affiliations
Dr. Deven Parmar
Keywords
Related Articles
- EP ID EP670320
- DOI -
- Views 119
- Downloads 0
PAKSHAGHATA – SAMPRAPTI AND CHIKITSA VIVECHANA
Pakshaghata means paralysis of one half of the body, here impairment of Karmendriyas, Gnyanendriyas and Manas seen. Pakshaghata can be correlated with hemiplegia which results from cerebrovascular accident - stroke. Stro...
EFFECT OF ETHANOLIC EXTRACT OF GARCINIA KOLA SEEDS ON FOETAL DEVELOPMENT
The incidence of children born with birth defects is 20% higher in Sub Saharan Africa than in developed countries and care must be taken to check the risk factors correlated to birth defects. Garcinia kola is used anecdo...
THE RISK OF OBESITY AND OBESITY RELATED DISEASES AMONG THE IGBO AND IJAW ADULTS IN NIGERIA USING WAIST-TO-HIP RATIO AS A MARKER.
This study was carried out to provide a baseline data for use by anthropologists and medical practitioners. The waist-to-hip ratio (WHR) of 1,588 adults were measured and used for the analysis of this study. Subjects wer...
POST-ENDODONTIC PAIN REDUCTION AFTER ONE AND TWO-VISITS ROOT CANAL TREATMENT IN TEETH WITH NECROTIC PULPS AND APICAL PERIODONTITIS WITH 3 PROTOCOLS OF IRRIGATION
Objective: The aim of this clinical trial was to assess whether controlled irrigation with three cryotherapy protocols with different temperature would result in a reduced of post-endodontic pain after one-visit and two...
GOVERNMENT PROGRAMMES IN CHECKING THE OCCURRENCE OF HABITAT LOSS AND THEIR IMPLICATIONS FOR MAINTAINING SUSTAINABLE ENVIRONMENT IN OGONI, RIVERS STATE, NIGERIA
The study set to find how government programmes can check the occurrence of habitat loss and their implication in maintaining a sustainable environment in Khana and Gokana local Government Areas in Ogoni of Rivers State....